Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) Research & Development (2016 - 2025)

Xtant Medical Holdings has reported Research & Development over the past 13 years, most recently at $634000.0 for Q3 2025.

  • Quarterly Research & Development fell 9.56% to $634000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Sep 2025, down 8.11% year-over-year, with the annual reading at $2.4 million for FY2024, 78.52% up from the prior year.
  • Research & Development was $634000.0 for Q3 2025 at Xtant Medical Holdings, up from $566000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $701000.0 in Q3 2024 and troughed at $151000.0 in Q4 2021.
  • The 5-year median for Research & Development is $262000.0 (2021), against an average of $376315.8.
  • Year-over-year, Research & Development fell 25.31% in 2023 and then soared 253.33% in 2024.
  • A 5-year view of Research & Development shows it stood at $151000.0 in 2021, then skyrocketed by 53.64% to $232000.0 in 2022, then surged by 112.07% to $492000.0 in 2023, then grew by 6.1% to $522000.0 in 2024, then grew by 21.46% to $634000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Research & Development are $634000.0 (Q3 2025), $566000.0 (Q2 2025), and $443000.0 (Q1 2025).